- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05058651
Evaluatie van de toevoeging van het immunotherapie-medicijn atezolizumab aan standaard chemotherapiebehandeling voor gevorderde of gemetastaseerde neuro-endocriene carcinomen die buiten de long ontstaan
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3).
II. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3).
III. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2).
SECONDARY OBJECTIVES:
I. To compare overall survival (OS), measured from start of observation/maintenance, across arms.
II. To compare progression free survival (PFS) (measured from randomization and measured from start of observation/maintenance) across arms.
III. To compare objective response rate (ORR = confirmed and unconfirmed partial response [PR] + confirmed and unconfirmed complete response [CR]) across arms among patients with measurable disease at randomization.
IV. To compare clinical benefit rate (CBR = confirmed and unconfirmed PR + confirmed and unconfirmed CR + stable disease [SD]) across arms among patients with measurable disease at randomization.
V. To compare duration of response (DOR) across arms. VI. To evaluate the safety and tolerability of each arm.
ADDITIONAL OBJECTIVE:
I. To bank tumor and blood samples for future biomarker correlative studies.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: During induction phase, patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (CLOSED TO ACCRUAL 7/9/26): During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.
ARM III: During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.
Patients in all arms also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial and blood sample collection on study.
After completion of study treatment, patients are followed up for 5 years.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alaska
-
Anchorage, Alaska, Verenigde Staten, 99508
- Geschorst
- Alaska Women's Cancer Care
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85004
- Werving
- Cancer Center at Saint Joseph's
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Phoenix, Arizona, Verenigde Staten, 85054
- Werving
- Mayo Clinic Hospital in Arizona
-
Hoofdonderzoeker:
- Jacob Orme
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-776-0015
-
-
California
-
Anaheim, California, Verenigde Staten, 92806
- Werving
- Kaiser Permanente-Anaheim
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Auburn, California, Verenigde Staten, 95602
- Werving
- Sutter Auburn Faith Hospital
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Auburn, California, Verenigde Staten, 95603
- Werving
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Baldwin Park, California, Verenigde Staten, 91706
- Werving
- Kaiser Permanente-Baldwin Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Bellflower, California, Verenigde Staten, 90706
- Werving
- Kaiser Permanente-Bellflower
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Berkeley, California, Verenigde Staten, 94704
- Werving
- Alta Bates Summit Medical Center-Herrick Campus
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Cameron Park, California, Verenigde Staten, 95682
- Werving
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Carmichael, California, Verenigde Staten, 95608
- Werving
- Mercy San Juan Medical Center
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@commonspirit.org
-
Carmichael, California, Verenigde Staten, 95608
- Werving
- Mercy Cancer Center - Carmichael
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Elk Grove, California, Verenigde Staten, 95758
- Werving
- Mercy Cancer Center - Elk Grove
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Fontana, California, Verenigde Staten, 92335
- Werving
- Kaiser Permanente-Fontana
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Fremont, California, Verenigde Staten, 94538
- Werving
- Palo Alto Medical Foundation-Fremont
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Harbor City, California, Verenigde Staten, 90710
- Werving
- Kaiser Permanente South Bay
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Irvine, California, Verenigde Staten, 92618
- Werving
- Kaiser Permanente-Irvine
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Los Angeles, California, Verenigde Staten, 90027
- Werving
- Kaiser Permanente Los Angeles Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Los Angeles, California, Verenigde Staten, 90034
- Werving
- Kaiser Permanente West Los Angeles
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Modesto, California, Verenigde Staten, 95355
- Werving
- Memorial Medical Center
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Mountain View, California, Verenigde Staten, 94040
- Werving
- Palo Alto Medical Foundation-Camino Division
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Ontario, California, Verenigde Staten, 91761
- Werving
- Kaiser Permanente-Ontario
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Palo Alto, California, Verenigde Staten, 94301
- Werving
- Palo Alto Medical Foundation Health Care
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Panorama City, California, Verenigde Staten, 91402
- Werving
- Kaiser Permanente - Panorama City
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Riverside, California, Verenigde Staten, 92505
- Werving
- Kaiser Permanente-Riverside
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Rocklin, California, Verenigde Staten, 95765
- Werving
- Mercy Cancer Center - Rocklin
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Roseville, California, Verenigde Staten, 95661
- Werving
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Roseville, California, Verenigde Staten, 95661
- Werving
- Sutter Roseville Medical Center
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Sacramento, California, Verenigde Staten, 95816
- Werving
- Sutter Medical Center Sacramento
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Sacramento, California, Verenigde Staten, 95816
- Werving
- Mercy Cancer Center - Sacramento
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
San Diego, California, Verenigde Staten, 92120
- Werving
- Kaiser Permanente-San Diego Zion
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
San Francisco, California, Verenigde Staten, 94115
- Werving
- California Pacific Medical Center-Pacific Campus
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
San Marcos, California, Verenigde Staten, 92078
- Werving
- Kaiser Permanente-San Marcos
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
Santa Cruz, California, Verenigde Staten, 95065
- Werving
- Palo Alto Medical Foundation-Santa Cruz
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Santa Rosa, California, Verenigde Staten, 95403
- Werving
- Sutter Pacific Medical Foundation
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- Telefoonnummer: 415-209-2683
- E-mail: clinicalresearch@sutterhealth.org
-
Sunnyvale, California, Verenigde Staten, 94086
- Werving
- Palo Alto Medical Foundation-Sunnyvale
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Vallejo, California, Verenigde Staten, 94589
- Werving
- Sutter Solano Medical Center/Cancer Center
-
Hoofdonderzoeker:
- Kristie A. Bobolis
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Woodland, California, Verenigde Staten, 95695
- Werving
- Woodland Memorial Hospital
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Woodland Hills, California, Verenigde Staten, 91367
- Werving
- Kaiser Permanente-Woodland Hills
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Hoofdonderzoeker:
- Helen H. Moon
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80210
- Werving
- AdventHealth Porter
-
Contact:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Hoofdonderzoeker:
- Yousuf A. Gaffar
-
Littleton, Colorado, Verenigde Staten, 80122
- Werving
- AdventHealth Littleton
-
Contact:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Hoofdonderzoeker:
- Yousuf A. Gaffar
-
Parker, Colorado, Verenigde Staten, 80138
- Werving
- AdventHealth Parker
-
Contact:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Hoofdonderzoeker:
- Yousuf A. Gaffar
-
-
Connecticut
-
Derby, Connecticut, Verenigde Staten, 06418
- Werving
- Smilow Cancer Hospital-Derby Care Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Fairfield, Connecticut, Verenigde Staten, 06824
- Werving
- Smilow Cancer Hospital Care Center-Fairfield
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Glastonbury, Connecticut, Verenigde Staten, 06033
- Geschorst
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Verenigde Staten, 06830
- Werving
- Smilow Cancer Hospital Care Center at Greenwich
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Guilford, Connecticut, Verenigde Staten, 06437
- Werving
- Smilow Cancer Hospital Care Center - Guilford
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Hartford, Connecticut, Verenigde Staten, 06105
- Geschorst
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Verenigde Staten, 06520
- Werving
- Yale University
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
North Haven, Connecticut, Verenigde Staten, 06473
- Werving
- Yale-New Haven Hospital North Haven Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Stamford, Connecticut, Verenigde Staten, 06902
- Werving
- Smilow Cancer Hospital Care Center at Long Ridge
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Torrington, Connecticut, Verenigde Staten, 06790
- Werving
- Smilow Cancer Hospital-Torrington Care Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Trumbull, Connecticut, Verenigde Staten, 06611
- Werving
- Smilow Cancer Hospital Care Center-Trumbull
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Waterbury, Connecticut, Verenigde Staten, 06708
- Werving
- Smilow Cancer Hospital-Waterbury Care Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
Waterford, Connecticut, Verenigde Staten, 06385
- Werving
- Smilow Cancer Hospital Care Center - Waterford
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33308
- Werving
- Holy Cross Hospital
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- E-mail: eileen.georgi@holy-cross.com
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Werving
- Mayo Clinic in Florida
-
Hoofdonderzoeker:
- Jacob Orme
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-776-0015
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Hoofdonderzoeker:
- Mintallah Haider
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Werving
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-524-6115
- E-mail: i.webster@hawaiicancercare.com
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Werving
- Queen's Cancer Cenrer - POB I
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-532-0315
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Werving
- Queen's Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-545-8548
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Werving
- Straub Clinic and Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-522-4333
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Werving
- University of Hawaii Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-586-2979
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Verenigde Staten, 96817
- Werving
- Queen's Cancer Center - Kuakini
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-531-8521
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- Werving
- Hawaii Cancer Care - Westridge
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-539-2273
- E-mail: info@hawaiicancercare.com
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- Geschorst
- Pali Momi Medical Center
-
‘Ewa Beach, Hawaii, Verenigde Staten, 96706
- Werving
- The Queen's Medical Center - West Oahu
-
Contact:
- Site Public Contact
- E-mail: rohta@queens.org
-
Hoofdonderzoeker:
- Elizabeth S. Nakasone
-
-
Idaho
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Werving
- Kootenai Health - Coeur d'Alene
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Nampa, Idaho, Verenigde Staten, 83687
- Werving
- Saint Alphonsus Cancer Care Center-Nampa
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Post Falls, Idaho, Verenigde Staten, 83854
- Werving
- Kootenai Clinic Cancer Services - Post Falls
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Werving
- Kootenai Clinic Cancer Services - Sandpoint
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Aurora, Illinois, Verenigde Staten, 60504
- Geschorst
- Rush-Copley Medical Center
-
Centralia, Illinois, Verenigde Staten, 62801
- Werving
- Centralia Oncology Clinic
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Ardaman Shergill
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern University
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Danville, Illinois, Verenigde Staten, 61832
- Werving
- Carle at The Riverfront
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
DeKalb, Illinois, Verenigde Staten, 60115
- Werving
- Northwestern Medicine Cancer Center Kishwaukee
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Cancer Care Specialists of Illinois - Decatur
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Decatur Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Crossroads Cancer Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Geneva, Illinois, Verenigde Staten, 60134
- Werving
- Northwestern Medicine Cancer Center Delnor
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Verenigde Staten, 60026
- Werving
- Northwestern Medicine Glenview Outpatient Center
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Grayslake, Illinois, Verenigde Staten, 60030
- Werving
- Northwestern Medicine Grayslake Outpatient Center
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Harvey, Illinois, Verenigde Staten, 60426
- Werving
- Ingalls Memorial Hospital
-
Hoofdonderzoeker:
- James A. Wallace
-
Contact:
- Site Public Contact
- Telefoonnummer: 708-915-4673
- E-mail: clinicaltrials@ingalls.org
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Werving
- Northwestern Medicine Lake Forest Hospital
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Mattoon, Illinois, Verenigde Staten, 61938
- Werving
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Mount Vernon, Illinois, Verenigde Staten, 62864
- Werving
- SSM Health Good Samaritan
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 618-899-1894
- E-mail: gayla.hall@ssmhealth.com
-
New Lenox, Illinois, Verenigde Staten, 60451
- Werving
- UC Comprehensive Cancer Center at Silver Cross
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Ardaman Shergill
-
Normal, Illinois, Verenigde Staten, 61761
- Werving
- Carle BroMenn Medical Center
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Normal, Illinois, Verenigde Staten, 61761
- Werving
- Carle Cancer Institute Normal
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- Cancer Care Center of O'Fallon
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Orland Park, Illinois, Verenigde Staten, 60462
- Werving
- University of Chicago Medicine-Orland Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Ardaman Shergill
-
Orland Park, Illinois, Verenigde Staten, 60462
- Werving
- Northwestern Medicine Orland Park
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Rockford, Illinois, Verenigde Staten, 61114
- Werving
- UW Health Carbone Cancer Center Rockford
-
Contact:
- Site Public Contact
- Telefoonnummer: 779-696-9378
- E-mail: lkline@uwhealth.org
-
Hoofdonderzoeker:
- Fahrettin Covut
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Southern Illinois University School of Medicine
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-545-7929
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Springfield Clinic
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-444-7541
-
Springfield, Illinois, Verenigde Staten, 62781
- Werving
- Springfield Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Warrenville, Illinois, Verenigde Staten, 60555
- Werving
- Northwestern Medicine Cancer Center Warrenville
-
Hoofdonderzoeker:
- Mary F. Mulcahy
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Yorkville, Illinois, Verenigde Staten, 60560
- Geschorst
- Rush-Copley Healthcare Center
-
-
Indiana
-
Crown Point, Indiana, Verenigde Staten, 46307
- Werving
- UChicago Medicine Northwest Indiana
-
Hoofdonderzoeker:
- Ardaman Shergill
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Werving
- Mary Greeley Medical Center
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
Ames, Iowa, Verenigde Staten, 50010
- Werving
- McFarland Clinic - Ames
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-239-4734
- E-mail: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, Verenigde Staten, 50023
- Werving
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Boone, Iowa, Verenigde Staten, 50036
- Geschorst
- McFarland Clinic - Boone
-
Carroll, Iowa, Verenigde Staten, 51401
- Werving
- Saint Anthony Regional Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-689-7658
- E-mail: sbenson@iora.org
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Clive, Iowa, Verenigde Staten, 50325
- Werving
- Mercy Cancer Center-West Lakes
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Richard L. Deming
-
Clive, Iowa, Verenigde Staten, 50325
- Werving
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Creston, Iowa, Verenigde Staten, 50801
- Actief, niet wervend
- Greater Regional Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- Broadlawns Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-282-2200
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- Mercy Medical Center - Des Moines
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Richard L. Deming
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- Iowa Methodist Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-6727
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, Verenigde Staten, 50501
- Werving
- McFarland Clinic - Trinity Cancer Center
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
Jefferson, Iowa, Verenigde Staten, 50129
- Geschorst
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Verenigde Staten, 50158
- Werving
- McFarland Clinic - Marshalltown
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
Waukee, Iowa, Verenigde Staten, 50263
- Werving
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
West Des Moines, Iowa, Verenigde Staten, 50266
- Werving
- Mercy Medical Center-West Lakes
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Richard L. Deming
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70805
- Werving
- LSU Health Baton Rouge-North Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-765-7659
- E-mail: research@ololrmc.com
-
Hoofdonderzoeker:
- Marshall P. Stagg
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Werving
- Our Lady of the Lake Physician Group
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-765-7659
- E-mail: research@ololrmc.com
-
Hoofdonderzoeker:
- Marshall P. Stagg
-
Metairie, Louisiana, Verenigde Staten, 70006
- Werving
- East Jefferson General Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Tara Castellano
-
Metairie, Louisiana, Verenigde Staten, 70006
- Werving
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Tara Castellano
-
New Orleans, Louisiana, Verenigde Staten, 70112
- Werving
- University Medical Center New Orleans
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Tara Castellano
-
-
Massachusetts
-
Burlington, Massachusetts, Verenigde Staten, 01805
- Werving
- Lahey Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 781-744-3421
- E-mail: lhmc-cancer-clinical-trials@lahey.org
-
Hoofdonderzoeker:
- Andrew Piper-Vallillo
-
Peabody, Massachusetts, Verenigde Staten, 01960
- Werving
- Lahey Clinic Peabody
-
Contact:
- Site Public Contact
- Telefoonnummer: 781-744-3421
- E-mail: lhmc-cancer-clinical-trials@lahey.org
-
Hoofdonderzoeker:
- Andrew Piper-Vallillo
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan Rogel Cancer Center
-
Hoofdonderzoeker:
- Vaibhav Sahai
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-865-1125
- E-mail: CancerAnswerLine@med.umich.edu
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Werving
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Battle Creek, Michigan, Verenigde Staten, 49017
- Werving
- Bronson Battle Creek
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health Medical Center - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Brownstown, Michigan, Verenigde Staten, 48183
- Werving
- Henry Ford Cancer Institute-Downriver
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health Medical Center - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Clinton Township, Michigan, Verenigde Staten, 48038
- Werving
- Henry Ford Macomb Hospital-Clinton Township
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Dearborn, Michigan, Verenigde Staten, 48126
- Werving
- Henry Ford Medical Center-Fairlane
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Dearborn, Michigan, Verenigde Staten, 48124
- Werving
- Corewell Health Dearborn Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 248-551-7695
-
Hoofdonderzoeker:
- Andrew A. Muskovitz
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Detroit, Michigan, Verenigde Staten, 48201
- Actief, niet wervend
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Verenigde Staten, 48236
- Werving
- Henry Ford Health Saint John Hospital
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: Kkeenan1@hfhs.org
-
East China Township, Michigan, Verenigde Staten, 48054
- Werving
- Henry Ford River District Hospital
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Farmington Hills, Michigan, Verenigde Staten, 48334
- Actief, niet wervend
- Weisberg Cancer Treatment Center
-
Farmington Hills, Michigan, Verenigde Staten, 48336
- Werving
- Corewell Health Farmington Hills Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 248-551-7695
-
Hoofdonderzoeker:
- Andrew A. Muskovitz
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Genesys Hurley Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Hurley Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Flint, Michigan, Verenigde Staten, 48503
- Geschorst
- Genesee Hematology Oncology PC
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Cancer Hematology Centers - Flint
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Werving
- Trinity Health Grand Rapids Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Werving
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Werving
- Henry Ford Saint John Hospital - Breast
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: karen.forman@ascension.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Werving
- Henry Ford Saint John Hospital - Academic
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Werving
- Henry Ford Saint John Hospital - Van Elslander
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Jackson, Michigan, Verenigde Staten, 49201
- Werving
- Allegiance Health
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Werving
- Bronson Methodist Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Werving
- West Michigan Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Lansing, Michigan, Verenigde Staten, 48910
- Actief, niet wervend
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Livonia, Michigan, Verenigde Staten, 48154
- Werving
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Macomb, Michigan, Verenigde Staten, 48044
- Werving
- Henry Ford Warren Hospital - Breast Macomb
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Macomb, Michigan, Verenigde Staten, 48044
- Werving
- Henry Ford Saint John Hospital - Macomb Medical
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Muskegon, Michigan, Verenigde Staten, 49444
- Werving
- Trinity Health Muskegon Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Niles, Michigan, Verenigde Staten, 49120
- Werving
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Norton Shores, Michigan, Verenigde Staten, 49444
- Geschorst
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, Verenigde Staten, 48377
- Werving
- Henry Ford Medical Center-Columbus
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Reed City, Michigan, Verenigde Staten, 49677
- Werving
- Corewell Health Reed City Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Werving
- Corewell Health William Beaumont University Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 248-551-7695
-
Hoofdonderzoeker:
- Andrew A. Muskovitz
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Werving
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Werving
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Traverse City, Michigan, Verenigde Staten, 49684
- Werving
- Munson Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Troy, Michigan, Verenigde Staten, 48085
- Werving
- Corewell Health Beaumont Troy Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 248-551-7695
-
Hoofdonderzoeker:
- Andrew A. Muskovitz
-
Warren, Michigan, Verenigde Staten, 48093
- Werving
- Henry Ford Madison Heights Hospital - Breast
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Warren, Michigan, Verenigde Staten, 48093
- Werving
- Henry Ford Health Warren Hospital
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Warren, Michigan, Verenigde Staten, 48093
- Werving
- Henry Ford Warren Hospital - GLCMS
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
West Bloomfield, Michigan, Verenigde Staten, 48322
- Werving
- Henry Ford West Bloomfield Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Wyandotte, Michigan, Verenigde Staten, 48192
- Werving
- Henry Ford Wyandotte Hospital
-
Hoofdonderzoeker:
- Haythem Y. Ali
-
Contact:
- Site Public Contact
- E-mail: nhay@hfhs.org
-
Wyoming, Michigan, Verenigde Staten, 49519
- Werving
- University of Michigan Health - West
-
Contact:
- Site Public Contact
- Telefoonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Hoofdonderzoeker:
- Kathleen Y. Butler
-
Ypsilanti, Michigan, Verenigde Staten, 48106
- Werving
- Huron Gastroenterology PC
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Werving
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Tareq Al baghdadi
-
-
Minnesota
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Werving
- Minnesota Oncology - Burnsville
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Duluth, Minnesota, Verenigde Staten, 55805
- Actief, niet wervend
- Saint Luke's Hospital of Duluth
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Fairview Southdale Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Minnesota Oncology - Edina
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Abbott-Northwestern Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Werving
- Hennepin County Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic in Rochester
-
Hoofdonderzoeker:
- Jacob Orme
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-776-0015
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Werving
- Park Nicollet Clinic - Saint Louis Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Werving
- Regions Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- Werving
- United Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Shakopee, Minnesota, Verenigde Staten, 55379
- Werving
- Saint Francis Regional Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Werving
- Saint Francis Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 573-334-2230
- E-mail: sfmc@sfmc.net
-
Joplin, Missouri, Verenigde Staten, 64804
- Werving
- Mercy Hospital Joplin
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 417-556-3074
- E-mail: esmeralda.carrillo@mercy.net
-
Springfield, Missouri, Verenigde Staten, 65804
- Werving
- Mercy Hospital Springfield
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 417-269-4520
-
Springfield, Missouri, Verenigde Staten, 65807
- Werving
- CoxHealth South Hospital
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 417-269-4520
-
St Louis, Missouri, Verenigde Staten, 63128
- Werving
- Mercy Hospital South
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Werving
- Community Hospital of Anaconda
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Verenigde Staten, 59101
- Werving
- Billings Clinic Cancer Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-996-2663
- E-mail: research@billingsclinic.org
-
Billings, Montana, Verenigde Staten, 59102
- Werving
- Saint Vincent Frontier Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-648-6274
-
Hoofdonderzoeker:
- Patrick W. Cobb
-
Great Falls, Montana, Verenigde Staten, 59405
- Werving
- Benefis Sletten Cancer Institute
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Verenigde Staten, 59901
- Werving
- Logan Health Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Verenigde Staten, 59804
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Werving
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Hoofdonderzoeker:
- Kathryn C. Hourdequin
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Actief, niet wervend
- Roswell Park Cancer Institute
-
New York, New York, Verenigde Staten, 10029
- Actief, niet wervend
- Mount Sinai Hospital
-
Stony Brook, New York, Verenigde Staten, 11794
- Actief, niet wervend
- Stony Brook University Medical Center
-
-
North Carolina
-
Cary, North Carolina, Verenigde Staten, 27518
- Geschorst
- Duke Cancer Center Cary
-
Charlotte, North Carolina, Verenigde Staten, 28203
- Werving
- Carolinas Medical Center/Levine Cancer Institute
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
Charlotte, North Carolina, Verenigde Staten, 28210
- Werving
- Atrium Health Pineville/LCI-Pineville
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 980-442-2000
-
Charlotte, North Carolina, Verenigde Staten, 28211
- Werving
- Levine Cancer Institute-SouthPark
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 980-442-2000
-
Charlotte, North Carolina, Verenigde Staten, 28262
- Werving
- Atrium Health University City/LCI-University
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
Charlotte, North Carolina, Verenigde Staten, 28277
- Werving
- Levine Cancer Institute-Ballantyne
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
Clinton, North Carolina, Verenigde Staten, 28328
- Werving
- Southeastern Medical Oncology Center-Clinton
-
Contact:
- Site Public Contact
- Telefoonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Concord, North Carolina, Verenigde Staten, 28025
- Werving
- Atrium Health Cabarrus/LCI-Concord
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-275-3853
-
Hoofdonderzoeker:
- Tucker Coston
-
Gastonia, North Carolina, Verenigde Staten, 28054
- Werving
- Levine Cancer Institute-Gaston
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
Goldsboro, North Carolina, Verenigde Staten, 27534
- Werving
- Southeastern Medical Oncology Center-Goldsboro
-
Contact:
- Site Public Contact
- Telefoonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Verenigde Staten, 28546
- Werving
- Southeastern Medical Oncology Center-Jacksonville
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Contact:
- Site Public Contact
- Telefoonnummer: 910-587-9084
- E-mail: jfields@cancersmoc.com
-
Pinehurst, North Carolina, Verenigde Staten, 28374
- Werving
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 910-715-3500
- E-mail: jcwilliams@firsthealth.org
-
Hoofdonderzoeker:
- Charles S. Kuzma
-
Raleigh, North Carolina, Verenigde Staten, 27609
- Werving
- Duke Cancer Center Raleigh
-
Contact:
- Site Public Contact
- E-mail: NCTNStudyTeam@dm.duke.edu
-
Hoofdonderzoeker:
- Tucker Coston
-
Shelby, North Carolina, Verenigde Staten, 28150
- Werving
- Atrium Health Cleveland/LCI-Cleveland
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Hoofdonderzoeker:
- Bhavana Konda
-
Toledo, Ohio, Verenigde Staten, 43623
- Geschorst
- Toledo Clinic Cancer Centers-Toledo
-
-
Oklahoma
-
Lawton, Oklahoma, Verenigde Staten, 73505
- Werving
- Cancer Centers of Southwest Oklahoma Research
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-231-4440
-
Hoofdonderzoeker:
- Sagila George
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Hoofdonderzoeker:
- Sagila George
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Werving
- Mercy Hospital Oklahoma City
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-752-3402
-
-
Oregon
-
Bend, Oregon, Verenigde Staten, 97701
- Werving
- Saint Charles Health System
-
Contact:
- Site Public Contact
- Telefoonnummer: 541-706-2909
- E-mail: nosall@stcharleshealthcare.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Clackamas, Oregon, Verenigde Staten, 97015
- Geschorst
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Verenigde Staten, 97132
- Werving
- Providence Newberg Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Oregon City, Oregon, Verenigde Staten, 97045
- Werving
- Providence Willamette Falls Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Portland, Oregon, Verenigde Staten, 97213
- Werving
- Providence Portland Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Portland, Oregon, Verenigde Staten, 97225
- Werving
- Providence Saint Vincent Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
-
Pennsylvania
-
Chambersburg, Pennsylvania, Verenigde Staten, 17201
- Werving
- WellSpan Medical Oncology and Hematology
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-217-6020
-
Hoofdonderzoeker:
- Marianne Spengler
-
Ephrata, Pennsylvania, Verenigde Staten, 17522
- Werving
- Ephrata Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-721-4840
-
Hoofdonderzoeker:
- Marianne Spengler
-
Gettysburg, Pennsylvania, Verenigde Staten, 17325
- Werving
- Adams Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-441-7957
-
Hoofdonderzoeker:
- Marianne Spengler
-
Hanover, Pennsylvania, Verenigde Staten, 17331
- Werving
- WellSpan Medical Oncology and Hematology
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-632-1559
-
Hoofdonderzoeker:
- Marianne Spengler
-
Lebanon, Pennsylvania, Verenigde Staten, 17042
- Werving
- Sechler Family Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-741-8303
- E-mail: doxenberg@wellspan.org
-
Hoofdonderzoeker:
- Marianne Spengler
-
York, Pennsylvania, Verenigde Staten, 17403
- Werving
- WellSpan Health-York Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-441-7957
-
Hoofdonderzoeker:
- Marianne Spengler
-
York, Pennsylvania, Verenigde Staten, 17403
- Geschorst
- Cancer Care Associates of York
-
-
Rhode Island
-
Westerly, Rhode Island, Verenigde Staten, 02891
- Werving
- Smilow Cancer Hospital Care Center - Westerly
-
Contact:
- Site Public Contact
- Telefoonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Hoofdonderzoeker:
- Matthew Austin
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Geschorst
- Medical University of South Carolina
-
Rock Hill, South Carolina, Verenigde Staten, 29732
- Werving
- Levine Cancer Institute-Rock Hill
-
Hoofdonderzoeker:
- Earle F. Burgess
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-9376
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten, 57701
- Werving
- Rapid City Regional Hospital
-
Hoofdonderzoeker:
- Abdel-Ghani Azzouqa
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-755-2370
- E-mail: research@monument.health
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt University/Ingram Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-811-8480
-
Hoofdonderzoeker:
- Robert A. Ramirez
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Namrata I. Peswani
-
Dallas, Texas, Verenigde Staten, 75235
- Werving
- Parkland Memorial Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Namrata I. Peswani
-
Dallas, Texas, Verenigde Staten, 75237
- Werving
- UT Southwestern Simmons Cancer Center - RedBird
-
Hoofdonderzoeker:
- Namrata I. Peswani
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Namrata I. Peswani
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Tannaz Armaghany
-
Contact:
- Site Public Contact
- Telefoonnummer: 713-798-1354
- E-mail: burton@bcm.edu
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Ben Taub General Hospital
-
Hoofdonderzoeker:
- Tannaz Armaghany
-
Contact:
- Site Public Contact
- Telefoonnummer: 713-873-2000
-
Richardson, Texas, Verenigde Staten, 75080
- Werving
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Telefoonnummer: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Hoofdonderzoeker:
- Namrata I. Peswani
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- Huntsman Cancer Institute/University of Utah
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-424-2100
- E-mail: cancerinfo@hci.utah.edu
-
Hoofdonderzoeker:
- Heloisa P. Soares
-
-
Vermont
-
Saint Johnsbury, Vermont, Verenigde Staten, 05819
- Werving
- Dartmouth Cancer Center - North
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-639-6918
- E-mail: cancer.research.nurse@hitchcock.org
-
Hoofdonderzoeker:
- Kathryn C. Hourdequin
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington Medical Center - Montlake
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- David B. Zhen
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- David B. Zhen
-
-
West Virginia
-
Bridgeport, West Virginia, Verenigde Staten, 26330
- Werving
- United Hospital Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Hoofdonderzoeker:
- Nour Daboul
-
Morgantown, West Virginia, Verenigde Staten, 26506
- Werving
- West Virginia University Healthcare
-
Contact:
- Site Public Contact
- Telefoonnummer: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Hoofdonderzoeker:
- Nour Daboul
-
-
Wisconsin
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Werving
- Marshfield Medical Center-EC Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Werving
- Gundersen Lutheran Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Hoofdonderzoeker:
- David E. Marinier
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Werving
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- Medical College of Wisconsin
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-805-3666
-
Hoofdonderzoeker:
- Alexandria T. Phan
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Werving
- Marshfield Medical Center - Minocqua
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Werving
- Marshfield Medical Center-Rice Lake
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Werving
- Marshfield Medical Center-River Region at Stevens Point
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
Weston, Wisconsin, Verenigde Staten, 54476
- Werving
- Marshfield Medical Center - Weston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Dean A. Delmastro
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)
-
Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator
-
Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:
-
Participants who have received treatment for brain metastases must have:
- No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
- Discontinued all corticosteroids at least 14 days prior to registration
-
Participants with treatment-naive brain lesions must have:
- No lesion measuring > 2.0 cm in size in any axis
- MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
- No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
- No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
-
-
Participants must not have symptomatic central nervous system (CNS) metastases
-
Participants must not have known or suspected leptomeningeal disease
-
Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration
-
Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study
-
Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =< grade 1.
-
Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration
-
Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 [IL-2] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration
-
Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide
-
Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.
-
Participants must be >= 18 years of age
-
Participants must have a Zubrod performance status of =< 2 within 28 days prior to registration
-
Participants must have a complete medical history and physical exam within 28 days prior to registration
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Platelet count >= 100 x 10^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Serum total bilirubin =< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned
-
Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration
-
Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:
-
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
-
Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
-
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
-
-
Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina
-
Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery
-
Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia
-
Participants must not have known active tuberculosis
-
Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated
-
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated
-
Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration
-
Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant
-
Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist [registered trademark]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab
-
Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm I (atezolizumab, platinum drug, etoposide)
During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT scan
Andere namen:
Given IV
Andere namen:
|
|
Experimenteel: Arm II (atezolizumab, platinum drug, etoposide, observation)
During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26) |
Given IV
Andere namen:
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT scan
Andere namen:
Undergo observation
Andere namen:
Given IV
Andere namen:
|
|
Actieve vergelijker: Arm III (platinum drug, etoposide, observation)
During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT scan
Andere namen:
Undergo observation
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival
Tijdsspanne: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years
|
Log-rank tests stratified by the randomization stratification factors will be used for null hypothesis (efficacy) tests. Cox regression models stratified by the randomization stratification factors will be used for alternative hypothesis (futility) tests. |
From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival
Tijdsspanne: From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
|
Will be estimated using the Kaplan-Meier method and compared using log-rank tests. |
From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
|
|
Duration of response
Tijdsspanne: Time from date of initial response to date of progression or death, assessed up to 5 years
|
Will be estimated non-parametrically using cumulative incidence curves. |
Time from date of initial response to date of progression or death, assessed up to 5 years
|
|
Objective response rate (confirmed complete response [CR] or partial response [PR])
Tijdsspanne: Up to 5 years from study enrollment
|
Will be tabulated and compared between arms using Fisher's exact test. |
Up to 5 years from study enrollment
|
|
Clinical benefit rate (confirmed CR or PR of any amount of time or stable disease for 6 months or longer)
Tijdsspanne: Up to 5 years from study enrollment
|
Will be tabulated and compared between arms using Fisher's exact test. |
Up to 5 years from study enrollment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: David B Zhen, SWOG Cancer Research Network
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Health Services Administration
- Organische chemicaliën
- Onderzoekstechnieken
- Methoden
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Kwaliteit van de gezondheidszorg
- Koolhydraten
- Podophyllotoxine
- Tetrahydronaftalenes
- Naftalenen
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glucosiden
- Glycosiden
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Coördinatiecomplexen
- Elementen
- Metalen
- Chemie -technieken, analytisch
- Spectrumanalyse
- Metalen, zwaar
- Platinumverbindingen
- Uitkomstbeoordeling, gezondheidszorg
- Uitkomst en procesbeoordeling, gezondheidszorg
- Overgangselementen
- Etoposide
- Carboplatine
- Cisplatine
- 1,2-diaminocyclohexaanplatina II-citraat
- Observatie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- Waakzaam wachten
- Platina
- atezolizumab
Andere studie-ID-nummers
- NCI-2021-09851
- U10CA180888 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2021-09851 (Register-ID: CTRP (Clinical Trial Reporting Program))
- S2012 (Andere identificatie: CTEP)
- S2012 (Andere identificatie: SWOG)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .